IX001 TCR-T Injection

TCR-T cell therapy targeting KRAS G12V mutation · Sun Yat-sen University

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IX001 TCR-T Injection, covering 2026-01-08 to 2026-01-08. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation [Phase 1]

See pricing